Cure Genetics and Frametact Limited Enter collabor...
2023.09.14
Cure Genetics and Frametact Limited Enter collabor...
Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement.

More

>
Dr. Shawn He Named Chief Scientific Officer at Cur...
2023.08.01
Dr. Shawn He Named Chief Scientific Officer at Cur...
Cure Genetics is delighted to announce that Dr. Shawn He will officially take up his post as the Chief Scientific Officer (CSO) in cell therapy on August 1, 2023. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines.

More

>
Cure Genetics and Frametact Reach a $60 Million Co...
2023.09.14
Cure Genetics and Frametact Reach a $60 Million Co...
Cure Genetics and Frametact Limited jointly announce the signing of a collaborative development and licensing agreement. The partnership will leverage Cure Genetics' proprietary VELPTM platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases.

More

>
Robert R. Ruffolo Joins CureGenetics's Scientific ...
2022.04.01
Robert R. Ruffolo Joins CureGenetics's Scientific ...
In April 2022, Suzhou, China, Cure Genetics, a biotechnology company focusing on development of cutting-edge gene and cell therapies, announced that Dr. Robert R. Ruffolo has joined its Scientific Advisory Board (SAB). Where he will provide scientific guidance to Cure Genetics technology platform and R&D pipeline, as well as assisting the Company’s global partnership effort.

More

>
Genevide, an incubation project of Cure Genetics, ...
2022.01.14
Genevide, an incubation project of Cure Genetics, ...
Recently, Genevide, an independent incubation company from Cure Genetics’s former molecular diagnostics business, announced the completion of a RMB 50 million angel round of financing led by Bioventure, co-invested by Qiming Ventures. Dr. Qiushi Li, former co-founder and COO of Cure Genetics, is named the co-founder and CEO of Genevide. “Genevide has built an Enzymes-mediated Duplex Exponential Amplification (EmDEATM) nPOCT technology platform with independent intellectual property portfolio using an innovative molecular enzyme cycle screening system based on enzyme characterization methods. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products. “ Dr. Qiushi Li, Co-Founder and CEO of Genevide said.

More

>